Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A non-hydrolyzable candesartan cilexetil analog reveals synergistic activation as a tractable mechanism for TMEM175 modulation.

American journal of physiology. Cell physiology·2026
Same author

Identification of potent and selective small molecule TALK-1 inhibitors that promote β-cell function.

Molecular pharmacology·2026
Same author

Phosphate: Not Just a CKD Problem?

Kidney360·2026
Same author

Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants.

American journal of physiology. Cell physiology·2026
Same author

Mechanism of Gating and Isoform-Specific Inhibition in Renal CLC Chloride Channels.

bioRxiv : the preprint server for biology·2026
Same author

Identification of Kir2.1 Inhibitors from a High-Throughput Screen.

Assay and drug development technologies·2026
Same journal

Blood Pressure Responses to Dietary Salt in Renin-Deficient Dahl Salt-Sensitive Rats.

American journal of physiology. Renal physiology·2026
Same journal

Cytokine Profiles in Patients with Chronic Kidney Disease and Low Sexual Function.

American journal of physiology. Renal physiology·2026
Same journal

Renovascular disease induces functionally relevant, locus-specific alterations to DNA methylation and hydroxymethylation in swine scattered tubular-like cells.

American journal of physiology. Renal physiology·2026
Same journal

Nitrite Protects Against Cardiac Surgery-Associated Acute Kidney Injury via Inflammation Suppression: Insights from a Rat Cardiopulmonary Bypass Model.

American journal of physiology. Renal physiology·2026
Same journal

Etanercept attenuates TNFα-mediated kidney injury in a rat model of brain death kidney donation.

American journal of physiology. Renal physiology·2026
Same journal

Phosphorylation of aquaporin-2 at serine 269 in urinary extracellular vesicles reflects renal vasopressin activity in rats.

American journal of physiology. Renal physiology·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

Novel diuretic targets.

Jerod S Denton1, Alan C Pao, Merritt Maduke

  • 1T4208 Medical Center North, 1161 21st Ave. South, Nashville, TN 37232. Jerod.S.Denton@Vanderbilt.edu.

American Journal of Physiology. Renal Physiology
|July 19, 2013
PubMed
Summary
This summary is machine-generated.

New diuretic targets in the kidney offer novel therapeutic opportunities for hypertension. Research is exploring small-molecule drugs for these targets to improve blood pressure management.

Keywords:
ClC-KKir4.1/5.1ROMKpendrinurea transporter

More Related Videos

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Related Experiment Videos

Last Updated: May 9, 2026

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Area of Science:

  • Nephrology
  • Pharmacology
  • Molecular Biology

Background:

  • Hypertension affects millions, with suboptimal blood pressure control in about half of treated patients.
  • Existing antihypertensive medications have limitations, necessitating diverse therapeutic options.
  • Novel drug targets are needed to improve treatment flexibility for an aging and diverse population.

Purpose of the Study:

  • To review emerging evidence implicating renal ion-transport proteins as novel diuretic targets.
  • To highlight progress in developing small-molecule pharmacology for these unexploited targets.

Main Methods:

  • Review of physiological, genetic, and pharmacological evidence.
  • Identification of key renal ion-transport proteins and regulators.
  • Analysis of current efforts in small-molecule drug development for these targets.

Main Results:

  • Several renal ion-transport proteins, including ROMK, Kir4.1/5.1, ClC-Ka/b, UTA/B, pendrin, and SPAK, are implicated as potential diuretic targets.
  • The molecular pharmacology for these targets is currently underdeveloped.
  • Initial progress has been made in developing small-molecule agents for some of these targets.

Conclusions:

  • Novel diuretic targets in the kidney present opportunities for new antihypertensive therapies.
  • Developing small-molecule drugs for these targets is crucial for improving blood pressure management.
  • Further research is needed to overcome the limitations in molecular pharmacology for these promising targets.